

JOINT COMPANY SECRETARY APPOINTMENT

PERTH, Australia and SAN FRANCISCO, California – 4 March 2026

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) is a precision medicine Company dedicated to changing the lives of patients with genetic diseases who have no treatment options available.

PYC advises that Mr Daniel Coletta has been appointed as joint Company Secretary of the Company effective immediately. Mr. Coletta has been appointed alongside PYC's longstanding joint Company Secretary, Mr. Kevin Hart, who will retire at the end of March 2026. Kevin was appointed as Company Secretary in July 2017. PYC's Board extend their thanks to Mr. Hart for his service and guidance to the Company over the last 9 years and wish him well in his retirement. Mr. Coletta has been appointed ahead of Mr. Hart's retirement to facilitate a seamless transition of company secretarial responsibilities.

Mr Coletta is an experienced Chartered Secretary appointed as Company Secretary to several ASX listed and unlisted public companies. Mr Coletta specialises in providing secretarial, governance, finance and corporate advisory services and is a Member of the Governance Institute of Australia and Chartered Accountants Australia & New Zealand.

For the purposes of ASX Listing Rule 12.6, Mr Coletta will be responsible for communications with ASX in relation to Listing Rule matters.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development ¹.

For more information, visit pyctx.com, or follow us on [LinkedIn](#) and [X](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

CONTACT US

Investor relations and media contact

investor@pyctx.com

